1. Home
  2. Flashcards
  3. Preview

AML with Recurrent Genetic Abnormalities (WHO 2008)

  1. t(8;21)(q22;q22)
    • RUNX1-RUNXT1
    • (formerly AML1/ETO)

    Favorable
  2. inv(16)(p13q22) or
    t(16;16)(p13;q22)
    CBFB-MYH11

    Favorable
  3. t(15;17)(q22;q12)
    PML-RARA

    Favorable (ATRA)
  4. t(9;11)(p22;q23)
    MLLT3-MLL

    • Intermediate but superior to AML
    • with other 11q23 abnormalities
  5. t(6;9)(p23;q34)
    DEK-NUP214

    Poor
  6. inv(3)(q21;q26) or
    t(3;3)(q21;q26)
    RPN-EVI1

    Poor
  7. t(1;22)(p13;q13)
    (megakaryoblastic)
    RBM15-MKL1

    • Previously poor; now responds
    • well to intensive chemo
  8. Variant RARA translocations in acute leukemia:
    • • t(5;17)(q35;q21) (NPM1-RARA): ATRA sensitive
    • • t(11;17)(q13;q21) (NUMA1-RARA): ATRA sensitive
    • • t(11;17)(q23;q21) (ZBTB16-RARA): ATRA resistant
    • • t(17;17)(q13;q21) (STAT5-RARA): ATRA resistant

    Must identify specific partner of RARA involved in translocation because of differing sensitivities to ATRA
  9. FLT3: tyrosine kinase receptor
    • • FLT3-ITD mutations (Internal Tandem Duplications within juxtamembrane
    • domain): associated with adverse outcome

    • • FLT3-TKD mutations (within 2nd Tyrosine Kinase domain): significance
    • controversial
  10. AML with mutated NPM1 (provisional entity)
    • Shows aberrant cytoplasmic expression of nucleophosmin (NPM)

    • • Favorable prognosis if present in setting of normal karyotype and in the
    • absence of FLT3-ITD mutation
  11. AML with mutated CEBPA (provisional entity)
    • Favorable prognosis if present in setting of normal karyotype (significance of
    • FLT3-ITD on prognosis remains to be clarified)
Author
elzotter
ID
77293
Card Set
AML with Recurrent Genetic Abnormalities (WHO 2008)
Description
cytogenetics, molecular, lymphoma
Updated

  1. Home
  2. Flashcards
  3. Preview